EyeCool Therapeutics Announces Publication of First Randomized Controlled Trial of Cooling Device

CAMBRIDGE, Mass. - Rezul -- EyeCool Therapeutics today announced the publication of the first randomized, double‑masked, multicenter clinical trial evaluating its investigational ocular surface cooling device for the treatment of chronic ocular surface pain (COSP) in Ophthalmology and Therapy. The study showed that a single in‑office treatment produced durable and clinically meaningful reductions in eye pain, along with significant improvement in corneal sensitivity, in patients with peripheral‑dominant pain phenotypes.

The trial, "A Randomized Double‑Masked Study Evaluating Safety and Efficacy of a Novel Topical Cooling Device for Chronic Ocular Surface Pain" (Galor et al., Ophthalmol Ther, 2026; doi:10.1007/s40123‑026‑01392‑3), enrolled adults with COSP to receive a one‑time, 4‑minute treatment with either the active or a sham handheld cooling device.

More on Rezul News

• Liora Opens in Delray Beach, Introducing a Boutique Community Designed Around Space, Privacy, and the Feeling of Home
• Avery Headley Leads Major Stabilization and Modernization Initiative Across Bronx Affordable Housing Portfolio
• NewReputation's AI Sentiment Analysis Tool Reaches 2,500 Users as Businesses Demand Clearer Brand Intelligence
• Treasure Coast of Florida Real Estate Trends for This Spring
• Andrew-Thomas Contractors Launches New HOA Fencing Services Page for Denver Metro Communities

In this prospective randomized, double masked controlled study, unilateral treatments were administered to 31 subjects with follow‑up to 8 weeks. Across three patient‑reported outcome measures, the active treatment arm demonstrated greater reductions in eye pain at week 8 than the sham arm, with all three exceeding thresholds for clinically meaningful improvement.

In a pre‑specified post hoc analysis of eyes with peripheral‑dominant pain, defined as a reduction in pain from a proparacaine challenge, eye pain severity improved significantly versus sham at week 8 (nominal p = 0.042) in one instrument, and overall eye pain showed a strong trend toward statistical significance (nominal p = 0.088) in another.

The device was well tolerated, with no serious adverse events reported. The most common adverse event was transient conjunctival hyperemia.

"The publication of this randomized, double‑masked study is an important step for patients living with chronic ocular surface pain," said Anat Galor, MD, MSPH, Bascom Palmer Eye Institute, University of Miami, and lead author of the study. "Not only did we see clinically meaningful improvements across multiple pain instruments, but we also observed that baseline corneal sensitivity, initially below normal in both arms, statistically significantly improved only in the actively treated group. This technology may address a critical unmet need in this population with limited effective options."

More on Rezul News

• CAPO Supply Announces Opening of Second Location in New Castle, Pennsylvania
• $224 Billion Growing Market in Life Settlements Presents Major Opportunity for New Policy Acquisition Business Plan: DLT Resolution Stock Symbol: DLTI
• FSBO Lead Launches Nationwide Platform Connecting Real Estate Investors with Local Field Agents
• Fyt-02 Launches on Kickstarter The Smart Sensor That Turns Any Chair Into a Posture & Movement Track
• AI Property Management: How AI in Property Management Is Improving Housing Operations

About EyeCool Therapeutics Inc.

EyeCool Therapeutics is a clinical stage medical device company committed to innovation and novel therapies for eye care. EyeCool is focused on developing an in-clinic device to deliver fast, lasting relief for patients suffering from Chronic Ocular Surface Pain.

Important Safety Information

Warning: This product has not been approved or cleared for marketing by the U.S. Food and Drug Administration and is considered an investigational device.

For more information, please visit www.eyecooltx.com.